More Stories

Informist, Wednesday, Aug. 5, 2026

 

Please click here to read all liners published on this story

--Neuland Lab Apr-Jun consol PAT INR 1.48 bln vs INR 139.00 mln year ago
--Neuland Lab Apr-Jun consol revenue INR 6.42 bln vs INR 2.93 bln year ago
--Gland Pharma, Neuland Labs sign pact for sterile API manufacturing
--Neuland Lab Q1 consol India revenue INR 832.64 mln vs INR 989.26 mln yr ago
--Neuland Lab Q1 consol Europe revenue INR 3.03 bln vs INR 944.12 mln yr ago
--Neuland Lab Q1 consol America revenue INR 2.0 bln vs INR 657.84 mln yr ago
--Neuland Lab Apr-Jun EBITDA INR 2.31 bln vs INR 421 mln yr ago 
--Neuland Lab Apr-Jun EBITDA margin 35.5% vs 14.0% yr ago 

 

By Pratyush Kumar

 

MUMBAI – Neuland Laboratories Ltd.'s net profit for the June quarter rose almost 11 times on a low base in the year-ago quarter, when the bottom line was dragged down by higher expenses. Revenues for Apr-Jun more than doubled and beat analysts' estimates.

 

The drugmaker's consolidated net profit for the June quarter was INR 1.48 billion, up from INR 139 million for the year-ago quarter. Sequentially, however, the net profit fell 30%. The Street had expected the bottom line to be between INR 409 million and INR 982 million.

 

Neuland Lab's consolidated net revenue from operations for the June quarter rose to INR 6.42 billion from INR 2.93 billion for the year-ago quarter. Sequentially, however, the revenue fell more than 17%. Analysts had estimated the revenue between INR 3.90 billion and INR 5.90 billion.

 

The company's total expenses for the June quarter grew 60% on year to INR 4.52 billion. The cost of materials consumed rose 42% to INR 2.28 billion. In the year-ago quarter, the cost of materials consumed was 55% of the company's revenues. In the quarter under review, this head of expense only accounted for a 35% drag. Similarly, in the year-ago quarter, the company had spent 25% of its revenues on employee benefit expenses. This time, the metric amounted to less than 17%.

 

Neuland Lab's earnings before interest, tax, depreciation, and amortisation for the June quarter were INR 2.31 billion, up from INR 421 million a year ago. The EBITDA margin expanded to 35.5% from 14.0%.

 

"Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS (custom manufacturing solutions and generic drug substances) businesses and represents a good start to the year," Saharsh Davuluri, chief executive officer and managing director, said. "While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects."

 

The company's consolidated revenue from the India segment was INR 832.64 million, down from INR 989.26 million a year ago. Sales from the Europe business rose sharply to INR 3.03 billion from INR 944.12 million. Revenues from the America business were INR 2 billion, also up sharply from INR 657.84 million.

 

The company said it has signed a pact with Gland Pharma Ltd. for a sterile manufacturing suite for active pharmaceutical ingredients. The suite will add nearly 1,400 kilograms of annual capacity for both companies.

Wednesday, shares of Neuland Laboratories ended at INR 19,956 apiece on the National Stock Exchange, up 3.5% from Tuesday. The company detailed its June quarter earnings post-market hours.  End

 

Edited by Shubhayan Bhattacharya

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.